Select Transactions

Global collaboration for the development and commercialization of ODM-208 with
$290 million upfront
July 2022
Sale to
$260 million
August 2021
Sale of 100%
equity stake to
Piramal Pharma Solutions
$106 million + milestones
June 2021
Equity investment from
Carlyle and Brighton Park
$200 million
February 2021
Torreya is a leading strategic M&A advisor to global life sciences companies.   MORE
Torreya is one of the most active financial advisors on pharmaceutical-product asset sales.   MORE
Torreya’s Capital Markets team arranges debt financings, royalty monetizations, IPOs, and private equity recapitalizations.   MORE
Torreya is a leading advisor on pre-commercial and commercial-stage licensing deals.   MORE

The Pharma 1000
Top Global Pharmaceutical Company Report

November 2021

Torreya report provides a snapshot of the global pharmaceutical industry in November 2021.

Click Here for Report Executive Summary   |   Full Report (pdf)